Physician profile
Adam C Walter
NPI 1114152543
$136,702.25
in general payments reported to CMS, 2019-2025
21 companies · $20K in 2025
The $20K reported for 2025 was more than what 94% of Gynecologic Oncology providers received nationally (typical 2025 total: $305).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $649 · 2020: $298 · 2021: $25K · 2022: $32K · 2023: $49K · 2024: $9,606 · 2025: $20K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Education: $48K · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $16K · Consulting Fee: $7,410 · Food and Beverage: $4,246 · Travel and Lodging: $2,278.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Education | $48,000.00 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $16,345.00 |
| Consulting Fee | $7,410.00 |
| Food and Beverage | $4,246.30 |
| Travel and Lodging | $2,277.68 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Intuitive Surgical, INC. | $83,508.17 | 2021-2025 | Da Vinci Surgical System, Da Vinci Sp |
| Eisai INC. | $46,894.18 | 2019-2025 | |
| Glaxosmithkline, LLC. | $4,623.50 | 2020-2024 | Zejula, Jemperli |
| Clovis Oncology, INC. | $452.85 | 2019-2022 | |
| Astrazeneca Pharmaceuticals Lp | $423.39 | 2019-2024 | Lynparza |
| Merck Sharp & Dohme LLC | $270.01 | 2019-2025 | Keytruda, Keytruda Qlex |
| Tesaro, INC. | $107.14 | 2019 | |
| Amgen INC. | $59.38 | 2019 | |
| Seagen INC. | $49.71 | 2022 | |
| Daiichi Sankyo INC. | $49.33 | 2019-2022 | |
| Kyowa Kirin, INC. | $40.32 | 2019-2020 | |
| Astellas Pharma US INC | $31.43 | 2023 | Veozah |
| Pfizer INC. | $30.74 | 2023-2024 | |
| Myriad Genetic Laboratories, INC. | $29.66 | 2021-2022 | |
| Immunogen, INC. | $24.29 | 2023 | Elahere |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ethicon US, LLC | $23.87 | 2021 | |
| Genentech USA, INC. | $23.46 | 2019 | |
| Fortovia Therapeutics, INC. | $18.54 | 2019 | |
| Blue Earth Diagnostics | $15.63 | 2019 | |
| Therapeuticsmd, INC. | $13.74 | 2019 | |
| Conmed Corporation | $12.91 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Adam Walter listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.